Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026

🌐 Laotian Times (HK) —

AI Summary

Akeso, Inc. announced positive overall survival results from its Phase III HARMONi-2 trial comparing Ivonescimab versus Pembrolizumab in first-line treatment for PD-L1-positive non-small cell lung cancer at the 2026 World Conference on Lung Cancer.

HONG KONG, Sept. 13, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC). The study evaluated the […]

Health Akeso lung cancer clinical trial HARMONi-2 study cancer treatment PD-L1 positive

Read original source →